Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-11-19 | 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide | Abbvie (USA - IL - previously Abbott) | chronic lymphocytic leukaemia |
Granting of the orphan status in the EU |
2012-11-19 | allopurinol sodium | Pharmathen (Greece) | perinatal asphyxia | |
2012-11-19 | artesunate | Dafra Pharma International (Belgium) | malaria |
Granting of the orphan status in the EU |
2012-11-19 | erdosteine | Rafifarm (Romania) | lead toxicity | |
2013-01-23 | exon 52 specific phosphorothioate oligonucleotide | Prosensa Therapeutics (The Netherlands) | Duchenne muscular dystrophy |
Granting of the orphan status in the US |
2013-01-25 | exon 55 specific phosphorothioate oligonucleotide | Prosensa Therapeutics (The Netherlands) | Duchenne muscular dystrophy |
Granting of the orphan status in the US |
2012-11-19 | humanised single chain monoclonal antibody against CD37 | Emergent Product Development UK (UK) | chronic lymphocytic leukaemia | |
2012-11-19 | maytansinoid-conjugated human monoclonal antibody against mesothelin (antibody drug conjugate ADC) | Bayer Healthcare (Germany) | malignant mesothelioma |
Granting of the orphan status in the EU |
2012-11-19 | triheptanoin | B.Braun Melsungen (Germany) | long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency |
Granting of the orphan status in the EU |
2012-11-19 | triheptanoin | B.Braun Melsungen (Germany) | very long-chain acyl-CoA dehydrogenase deficiency | |
2015-01-23 | meningococcal Group B vaccine [rDNA, component, adsorbed] | Novartis (Switzerland) | invasive meningococcal disease caused by serogroup B (also known as meningitis B) in adolescents and young adults from 10 years through 25 years of age immunisation of individuals over two months of age against invasive meningococcal disease caused by Neisseria meningitidis group B |
Granting of a Market Authorisation in the US |
2016-07-28 | lixisenatide | Sanofi (France) | Treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose-lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control |
Granting of a Market Authorisation in the US |
2015-11-13 | susoctocog alfa (recombinant porcine factor VIII - OBI-1) | Baxter (USA - IL) Baxalta Innovations (Germany) | acquired hemophilia A |
Granting of a Market Authorisation in the EU |
2012-11-21 | influenza virus vaccine | Novartis (Switzerland) | prevention of seasonal influenza for individuals 18 years of age and older |
|
2012-12-06 | SIMPLE Antibody™ platform | Argen-X (The Netherlands-Belgium) | ||
2013-09-23 | ustekinumab | Janssen Biotech - Janssen Biologics (J&J - USA) | active psoriatic arthritis |
Granting of a Market Authorisation in the US |
2012-12-07 | Apo E mimetic peptide | LipimetiX Development (UK-USA) | homozygous familial hypercholesterolemia (HoFH) | |
2012-12-11 | rituximab | Roche (Switzerland) | non-Hodgkin lymphoma | |
2012-12-11 | thyrotropin alfa for injection | Genzyme (USA - MA), a Sanofi company (France) | thyroid remnant ablation |
Granting of a Market Authorisation in the EU |
2012-12-13 | radium-223 dichloride | Bayer HealthCare (Germany) | castration-resistant prostate cancer (CRPC) patients with bone metastases |
Granting of a Market Authorisation in the EU |
© 2024 Biopharmanalyses - Powered by Samacom+